ISTA Pharmaceuticals Inc. (ISTA, Financial) filed Annual Report for the period ended 2010-12-31.
Ista Pharmaceuticals Inc. has a market cap of $221.5 million; its shares were traded at around $6.61 with and P/S ratio of 2. Hedge Fund Gurus that owns ISTA: Jim Simons of Renaissance Technologies LLC.
We have incurred losses since inception and have a stockholders deficit of approximately $79.1 million (including non-cash valuation warrant adjustments of $59.6 million) through December 31, 2010.
According to the Glaucoma Research Foundation, four million people in the U.S. suffer from the disease, with 120,000 new cases documented annually. Based on 2010 data from IMS Health, we estimate that the U.S. pharmaceutical market for the treatment of glaucoma exceeds $2.2 billion per year. Of this amount, the ophthalmic beta-blocker market was approximately $182 million in 2010 primarily at generic prices, with over 4.3 million prescriptions written in 2010.
T-PRED, if approved by the FDA, will compete in the antibiotic/steroid combination segment of the U.S. topical ophthalmic anti-inflammatory market. Based upon management estimates and 2010 prescription data compiled by IMS Health, we estimate that 2010 sales in the U.S. topical ophthalmic anti-inflammatory market were approximately $848 million, with total prescriptions of 11.5 million. In 2010, the combination antibiotic and steroid segment of the ophthalmic anti-inflammatory market had approximately a 36% share of the prescriptions or $302 million in prescription dollars and about 4 million prescriptions according to data compiled by IMS Health.
Read the The complete Report
Ista Pharmaceuticals Inc. has a market cap of $221.5 million; its shares were traded at around $6.61 with and P/S ratio of 2. Hedge Fund Gurus that owns ISTA: Jim Simons of Renaissance Technologies LLC.
Highlight of Business Operations:
We are a rapidly growing commercial-stage, multi-specialty pharmaceutical company developing, marketing and selling our own products in the U.S. and Puerto Rico. We are the fourth largest branded prescription eye care business in the U.S. and have an emerging allergy drug franchise. We manufacture our finished good products through third-party contracts, and we in-license or acquire new products and technologies to add to our internal development efforts from time to time. Our products and product candidates seek to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye and ocular and nasal allergies. The United States, or U.S., prescription markets for 2010 which our therapies seek to address include key segments of the $6.5 billion ophthalmic pharmaceutical market and the $2.5 billion nasal allergy market.We have incurred losses since inception and have a stockholders deficit of approximately $79.1 million (including non-cash valuation warrant adjustments of $59.6 million) through December 31, 2010.
According to the Glaucoma Research Foundation, four million people in the U.S. suffer from the disease, with 120,000 new cases documented annually. Based on 2010 data from IMS Health, we estimate that the U.S. pharmaceutical market for the treatment of glaucoma exceeds $2.2 billion per year. Of this amount, the ophthalmic beta-blocker market was approximately $182 million in 2010 primarily at generic prices, with over 4.3 million prescriptions written in 2010.
T-PRED, if approved by the FDA, will compete in the antibiotic/steroid combination segment of the U.S. topical ophthalmic anti-inflammatory market. Based upon management estimates and 2010 prescription data compiled by IMS Health, we estimate that 2010 sales in the U.S. topical ophthalmic anti-inflammatory market were approximately $848 million, with total prescriptions of 11.5 million. In 2010, the combination antibiotic and steroid segment of the ophthalmic anti-inflammatory market had approximately a 36% share of the prescriptions or $302 million in prescription dollars and about 4 million prescriptions according to data compiled by IMS Health.
Read the The complete Report
